Coronavirus disease 2019 (COVID-19) is an inflammatory process with complex pathophysiology and by affecting the cardiovascular system directly or indirectly that causes life threatening cardiac injuries . Therefore, clarifying the effects of this infection on the cardiovascular system is of importance in terms of the clinical course of the disease . The increases in cardiac and inflammatory biomarkers in COVID-19 have been associated with poor prognosis and mortality . However, there are no specific laboratory markers yet to assess the severity of the disease . In this context, the combination of available biomarkers is needed to better define the clinical course of this disease . Carbohydrate antigen 125 (CA-125) has become a remarkable marker in recent years as a result of the correlation of increasing levels in cardiovascular diseases with clinical, hemodynamic, echocardiographic parameters and its relation with mortality or re-hospitalization due to heart failure . These findings suggest that CA-125 might be useful biomarker to identify the damage mechanisms of COVID-19, monitoring the prognosis of the disease and the course of the treatment.